STANDARD BIOTOOLS INC. — Director's Dealing 2011

Feb 9, 2011

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: FLUIDIGM CORP (FLDM)
CIK: 0001162194
Period of Report: 2011-02-09

Reporting Person: Whitaker Raymond J (Director)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series E Preferred Warrant (Right to Buy)	$24.22		Common Stock (11924)		Indirect
Series E Preferred Stock	$0		Common Stock (47400)		Indirect
Series C Preferred Stock	$0		Common Stock (320063)		Indirect
Series D Preferred Stock	$0		Common Stock (66991)		Indirect
Series E Preferred Warrant (Right to Buy)	$24.22		Common Stock (11924)		Indirect
Series E Preferred Stock	$0		Common Stock (47400)		Indirect
Series C Preferred Stock	$0		Common Stock (320063)		Indirect
Series D Preferred Stock	$0		Common Stock (66991)		Indirect
Stock Option (Right to Buy)	$8.38		Common Stock (8670)		Direct
Stock Option (Right to Buy)	$4.45		Common Stock (8670)		Direct

Footnotes

F1: Reflects the automatic conversion of each share of Series E Preferred Stock into 1.3 shares of Common Stock to occur upon the closing of the Issuer's initial public offering.

F2: Expires immediately prior to the closing of the Issuer's initial public offering.

F3: Reflects a 1-for-1.73 reverse stock split of the Issuer's outstanding shares effected February 3, 2011.

F4: EuclidSR Partners, L.P., is the record holder of the securities reported on Lines 1, 2, 3 and 4 of Table 2.

F5: Mr. Whitaker, the reporting person who is a member of the Board of Directors of the Issuer shares voting and investment power with Graham D.S. Anderson, Milton J. Pappas and Stephen K. Reidy, each of whom are General Partners of EuclidSR Associates, L.P., the General Partner of EuclidSR Partners and EuclidSR Biotechnology Associates, L.P., the General Partner of EuclidSR Biotechnology Partners. Each General Partner of EuclidSR Associates, L.P. and EuclidSR Biotechnology Associates, L.P. disclaims beneficial ownership of the shares except to the extent of their pecuniary interest therein.

F6: Each share has no expiration date.

F7: Reflects the automatic conversion of each share of Series C Preferred Stock and Series D Preferred Stock into one share of Common Stock to occur upon the closing of the Issuer's initial public offering. Each share has no expiration date.

F8: EuclidSR Biotechnology Partners, L.P., is the record holder of the securities reported on Lines 5, 6, 7 and 8 of Table 2.

F9: 1/12th of the shares subject to such Option shall vest on each monthly anniversary of January 28, 2011 (the "Vesting Commencement Date"), such that the Option will be fully vested on the first annual anniversary of the Vesting Commencement Date. The Option shall expire on January 6, 2021.

F10: The Option fully vested on January 28, 2011. The Option shall expire on January 28, 2020.